CompletedNot Applicable

Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children

Pakistan42 participantsStarted 2023-12-01

Plain-language summary

Neonates with persistent pulmonary hypertension (PPH) should be administered inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO), but these are not available in most resource-constrained settings like ours. This study was planned to compare the outcomes of Milrinone plus Sildenafil versus Sildenafil alone in the treatment of PPH in neonates.

Who can participate

Age range1 Day – 28 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients of either gender * Aged between 1-28 days * Birth weight above 2000 grams * Diagnosed with persistent pulmonary hypertension (as per echocardiography) Exclusion Criteria: * Neonates having congenital heart defects (CHDs) * Congenital diaphragmatic hernia * Lung anomalies * History of any surgical intervention

What they're measuring

Change in pulmonary artery systolic pressure

Timeframe: 72 hours

Trial details

NCT IDNCT06562036

SponsorMuhammad Aamir Latif

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-31

View on ClinicalTrials.gov More Persistent Pulmonary Hypertension of the Newborn trials